1. A modified Cued Recall Test for detecting prodromal AD in adults with Down syndrome
- Author
-
Krinsky‐McHale, Sharon J, Hartley, Sigan, Hom, Christy, Pulsifer, Margaret, Clare, Isabel CH, Handen, Benjamin L, Lott, Ira T, Schupf, Nicole, Silverman, Wayne, and Investigators, for the Alzheimer's Biomarker Consortium—Down Syndrome
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Acquired Cognitive Impairment ,Alzheimer's Disease ,Neurosciences ,Dementia ,Aging ,Prevention ,Intellectual and Developmental Disabilities (IDD) ,Brain Disorders ,Neurodegenerative ,Down Syndrome ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,4.1 Discovery and preclinical testing of markers and technologies ,Neurological ,Alzheimer's disease ,cued recall ,dementia ,Down syndrome ,memory impairment ,mild cognitive impairment ,Alzheimer's Biomarker Consortium—Down Syndrome (ABC‐DS) Investigators ,Genetics ,Biological psychology - Abstract
IntroductionThe development of valid methods to diagnose prodromal Alzheimer's disease (AD) in adults with Down syndrome (DS) is one of the many goals of the Alzheimer's Biomarkers Consortium-Down Syndrome (ABC-DS).MethodsThe diagnostic utility of a modified Cued Recall Test (mCRT) was evaluated in 332 adults with DS ranging from 25 to 81 years of age. Total recall was selected a priori, as the primary indicator of performance. Multiple regression and receiver-operating characteristic (ROC) analyses were used to compare diagnostic groups.ResultsPerformance on the mCRT, as indicated by the total recall score, was highly sensitive to differences between diagnostic groups. ROC areas under the curve (AUCs) ranging from 0.843 to 0.955, were observed.DiscussionThe mCRT has strong empirical support for its use in clinical settings, as a valuable tool in studies targeting biomarkers of AD, and as a potential outcome measure in clinical trials targeting AD in this high-risk population.
- Published
- 2022